Abstract
The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted foreign sequences/transgene, its ability for reconversion, recombination and dissemination in the population and the environment are the main points of attention. Measures to prevent or manage identified risks are also discussed.
Keywords: Biosafety, clinical trials, environmental risk assessment, gene therapy, GMO-based vaccines, MVA-based recombinant vectors.
Current Gene Therapy
Title:Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
Volume: 13 Issue: 6
Author(s): Martine Goossens, Katia Pauwels, Nicolas Willemarck and Didier Breyer
Affiliation:
Keywords: Biosafety, clinical trials, environmental risk assessment, gene therapy, GMO-based vaccines, MVA-based recombinant vectors.
Abstract: The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted foreign sequences/transgene, its ability for reconversion, recombination and dissemination in the population and the environment are the main points of attention. Measures to prevent or manage identified risks are also discussed.
Export Options
About this article
Cite this article as:
Goossens Martine, Pauwels Katia, Willemarck Nicolas and Breyer Didier, Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors, Current Gene Therapy 2013; 13 (6) . https://dx.doi.org/10.2174/156652321306140103221941
DOI https://dx.doi.org/10.2174/156652321306140103221941 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Describing Evolution of Hemagglutinins from Influenza A Viruses Using a Differential Equation
Protein & Peptide Letters Gold Nanoparticle-Mediated High-Performance Enzyme-Linked Immunosorbent Assay for Detection of Tuberculosis ESAT-6 Protein
Micro and Nanosystems Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Infectious Disorders - Drug Targets The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Recent Advances in Optical Molecular Imaging and its Applications in Targeted Drug Delivery
Current Drug Targets Phenanthrene Dimers: Promising Source of Biologically Active Molecules
Current Topics in Medicinal Chemistry Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Notch Signaling in the Central Nervous System with Special Reference to its Expression in Microglia
CNS & Neurological Disorders - Drug Targets Comparative Analysis of Fruit and Vegetable Consumption in a Food Service Unit: Is it Possible to Influence the Choices?
The Natural Products Journal Evidence of Probiotics in Prevention of Allergy and Asthma
Current Drug Targets - Inflammation & Allergy miR-25 Mediates Retinal Degeneration Via Inhibiting ITGAV and PEDF in Rat
Current Molecular Medicine A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides
Current HIV Research Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping
Current Molecular Pharmacology Hair Growth: Focus on Herbal Therapeutic Agent
Current Drug Discovery Technologies